01.08.14
New research published ahead-of-print in the journal Cancer Prevention Research, suggests that the consumption of the root of Piper methysticum, or kava, may prevent the development of tobacco smoke-induced lung cancer.
Researchers at the University of Minnesota (UM) and Texas Tech University recently studied the effects of a special preparation of the kava root on lung cancer in mice, and have concluded that the chemically defined extract may have the potential to reduce the risk of lung cancer in humans.
In addition, the research team has identified the naturally occurring components of kava that appear responsible for all the cancer-preventative benefits. By using a patent-pending blend of these active kava ingredients, the research team was also able to avoid liver damage, a potential side effect previously associated with various commercially available kava-containing dietary supplements.
In the latest study, the University of Minnesota research team found daily consumption of a kava-derived dietary supplement prevented the formation of 99% of tumors in a mouse lung tumorigenesis model that is routinely used in predicting lung cancer behavior in humans. The unprecedented level of tumor prevention was coupled with the finding that some mice developed no tumors at all. DNA damage resulting from tobacco carcinogens was also significantly reduced by way of prevention, providing a clue to what is potentially behind kava’s effectiveness.
Researchers have proposed that perhaps these findings may help explain the low rate of cancer incidence where kava is traditionally consumed. Rates of cancer in the South Pacific Islands of Vanuatu, Fiji and Western Samoa are dramatically lower than those in countries with no kava consumption. Similarly, despite tobacco smoking rates comparable to those of the U.S., the occurrence of lung cancer in Fiji is just 5 to 10% of the U.S. lung cancer occurrence rate.
Preliminary data from University of Minnesota has identified the potential compound behind kava-related liver problems and human clinical trials for the new, patent-pending kava supplement enriched with cancer-preventative benefits alone are planned. The University of Minnesota research team is also pursuing development of kava-derived drugs that may aid in both the prevention and treatment of other types of cancers.
“This is highly interesting research and suggests a potential new use for certain preparations made from kava root and rhizome,” said Mark Blumenthal, founder and executive director of the nonprofit American Botanical Council (ABC). “Of course,” he added, “the preliminary results must be confirmed in human clinical trials.
Mr. Blumenthal noted that ABC policy on reporting of scientific and clinical research on herbs and their preparations designates that "ABC does not usually cover animal research in its scientific reporting, preferring human clinical trials. However, in this case ABC believes that the potential implications for human health and the herb kava are significant enough, as suggested by this particular animal research, to warrant attention by ABC."
According to Stefan Gafner, chief science officer of ABC, “The fact that the researchers were able to find evidence of the ability of a kava fraction to prevent the formation of tumors in mice, in support of epidemiological data showing a lower incidence of lung cancer in people living on the South Pacific Islands where kava is traditionally used, makes this study very compelling. If confirmed in human clinical studies, the results could have a big impact on human health and may lead to a greater emphasis on prevention rather than cure."
Researchers at the University of Minnesota (UM) and Texas Tech University recently studied the effects of a special preparation of the kava root on lung cancer in mice, and have concluded that the chemically defined extract may have the potential to reduce the risk of lung cancer in humans.
In addition, the research team has identified the naturally occurring components of kava that appear responsible for all the cancer-preventative benefits. By using a patent-pending blend of these active kava ingredients, the research team was also able to avoid liver damage, a potential side effect previously associated with various commercially available kava-containing dietary supplements.
In the latest study, the University of Minnesota research team found daily consumption of a kava-derived dietary supplement prevented the formation of 99% of tumors in a mouse lung tumorigenesis model that is routinely used in predicting lung cancer behavior in humans. The unprecedented level of tumor prevention was coupled with the finding that some mice developed no tumors at all. DNA damage resulting from tobacco carcinogens was also significantly reduced by way of prevention, providing a clue to what is potentially behind kava’s effectiveness.
Researchers have proposed that perhaps these findings may help explain the low rate of cancer incidence where kava is traditionally consumed. Rates of cancer in the South Pacific Islands of Vanuatu, Fiji and Western Samoa are dramatically lower than those in countries with no kava consumption. Similarly, despite tobacco smoking rates comparable to those of the U.S., the occurrence of lung cancer in Fiji is just 5 to 10% of the U.S. lung cancer occurrence rate.
Preliminary data from University of Minnesota has identified the potential compound behind kava-related liver problems and human clinical trials for the new, patent-pending kava supplement enriched with cancer-preventative benefits alone are planned. The University of Minnesota research team is also pursuing development of kava-derived drugs that may aid in both the prevention and treatment of other types of cancers.
“This is highly interesting research and suggests a potential new use for certain preparations made from kava root and rhizome,” said Mark Blumenthal, founder and executive director of the nonprofit American Botanical Council (ABC). “Of course,” he added, “the preliminary results must be confirmed in human clinical trials.
Mr. Blumenthal noted that ABC policy on reporting of scientific and clinical research on herbs and their preparations designates that "ABC does not usually cover animal research in its scientific reporting, preferring human clinical trials. However, in this case ABC believes that the potential implications for human health and the herb kava are significant enough, as suggested by this particular animal research, to warrant attention by ABC."
According to Stefan Gafner, chief science officer of ABC, “The fact that the researchers were able to find evidence of the ability of a kava fraction to prevent the formation of tumors in mice, in support of epidemiological data showing a lower incidence of lung cancer in people living on the South Pacific Islands where kava is traditionally used, makes this study very compelling. If confirmed in human clinical studies, the results could have a big impact on human health and may lead to a greater emphasis on prevention rather than cure."
